Medexus Pharmaceuticals Inc T.MDP

Alternate Symbol(s): MEDXF

Healthcare Biotechnology

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of oncology, hematology, rheumatology, autoimmune diseases, allergy, and dermatology. It operates through two segments: Medexus Pharma Canada and Medexus Pharma USA. Its lead products are IXINITY (US), Rupall (Canada), Rasuvo (US) and Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.

TSX:MDP - Post by User

Medexus Pharmaceuticals Inc

Bullboard Posts

Comment by TheRock07on Jul 22, 2016 10:02am

127 Views

Post# 25075450

RE:RE:RE:Another 2 Big Approvals coming this November & 2Q = 1000%

These three drugs have combined peak sales of $15 million net to PDP.

That should result in at least $3 million in the first year.

Along with $4.4 million forecast by management for Nyda, annual sales will be about $7.5 million.

At 10 times, fair market cap value at peer levels would be about $75 million or about $0.85 per share.

And that excludes cash, other acquired drugs etc..

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal